Email Updates

You are here

Home»Resources

Webinar & Meeting Reports

  • HIV Advocates’ Update on COVID-19

    March 23, 2020

    On Monday, March 23 we were joined by Dr. Carl Dieffenbach, Director of the Division of AIDS (DAIDS) at the NIH, Lillian Mworeko of ICW-EA and Yvette Raphael of APHA, to answer questions about what we do and don’t know about COVID-19 and HIV, how to track research developments on the HIV front, what this new pandemic might mean for ongoing HIV research, and how the HIV community can contribute to the fight against COVID-19.

  • CROI 2020

    March 8, 2020 to March 11, 2020

    The annual Conference on Retroviruses and Opportunistic Infections (CROI) will take place March 8-11 in Boston, Massachusetts. Read on to review the coverage, access webcasts of conference sessions and to check out what caught AVAC’s attention.

  • Webinar: HVTN 702 updates and next steps

    February 19, 2020

    Leaders of HVTN 702 HIV vaccine efficacy trial in South Africa (also known as Uhambo), announced that vaccinations would be stopped early because the vaccine candidate did not prevent HIV. AVAC and APHA held a global webinar to discuss the latest updates on these conversations and reflect on how they may impact HIV prevention globally.

  • Webinar: What’s New—and Next—for TB Vaccines

    February 6, 2020

    On Thursday, February 6, Treatment Action Group (TAG) and AVAC conducted a webinar featuring an update on recent vaccine results and possible next steps with M72/AS01E, one of several new TB vaccine candidates.

  • Biomedical HIV Prevention Summit

    December 3, 2019 to December 4, 2019

    The fourth annual Biomedical HIV Prevention Summit was held 3-4 December 2019 at the Marriott Marquis in Houston, Texas. NMAC believes we must highlight the role that biomedical prevention tools such as PrEP, PEP, Treatment as Prevention (TasP), and U=U have in ending the epidemic.

  • ICASA 2019

    December 2, 2019 to December 7, 2019

    The 20th International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA 2019) was December 2-7 in Kigali, Rwanda. Find details below on select events of interest. AVAC was there along with many of our partners and participated in sessions both before and during the conference.

  • World AIDS Day

    December 1, 2019

    World AIDS Day takes place on 1 December every year. It’s an opportunity for everyone to support people living with HIV/AIDS, commemorate those we have lost, take stock of the tireless work being done worldwide and re-energize advocacy efforts to end the epidemic.

  • Trial Design Takes a Step in the Post PrEP Era: What will Gilead’s study of F/TAF among cisgender women tell us about next gen PrEP and next gen trial design

    November 13, 2019

    The FDA’s October approval excluded F/TAF as PrEP “for those who have receptive vaginal sex.” Many voices have expressed outrage that Gilead’s strategy for F/TAF regulatory approval left women by the wayside. Gilead had previously claimed finding a relevant cohort of women would not be feasible. Gilead is designing a novel trial, planned to begin in Africa in 2020, to gather missing data about the safety and efficacy of F/TAF among cisgender women. What are the implications of this trial?

  • It’s Complicated: Implementation questions regarding price, programming and policies for Descovy as PrEP

    November 11, 2019

    Advocates, policy makers, funders and other stakeholders have surfaced a number of questions regarding Descovy (F/TAF) for PrEP – recently approved by the FDA to prevent HIV during anal sex. With Truvada (TDF/FTC) set to go off patent next year, several generic options waiting in the wings, and our community’s reliance on the 340B program for funding PrEP-related services, many have raised concerns about price, policy and programming related to Descovy.

  • Improving Access to Innovative HIV Technology

    October 22, 2019

    Two things need to happen to achieve greater success in the global fight against HIV: dramatically reduce new infections and achieve viral suppression in those already living with the virus. In order to meet these goals, new infections must come down from an annual rate of 1.7-2 million that has been stagnant for a decade, viral suppression must be sustained and ensured for the more than 23 million people living with HIV (PLHIV) on anti-retroviral treatment (ART), and treatment must be provided to the more than 14 million PLHIV not on ART.

Pages